Glaucoma, Secondary Cataract and Retinal Therapy All In One – Why Lumenis’ Smart Selecta Trio is the Solution to Eye Treatments
Innovation is advancing at unprecedented speed, and so are the efforts to find the gold standard protocol for unprecedented eye care.
The Lumenis Smart Selecta® Trio™ represents the next generation of multi-modality products, offering glaucoma, secondary cataract and advanced retinal therapies in a single platform. The unit’s integrated design, enhanced optics system and innovative laser cavity makes the Trio one of the highest performing laser products in the market, offering maximum flexibility with minimum footprint.
With all the advantages of the SLT and the Super Gaussian beam profile of the YAG mode, the Smart Selecta® Trio™ achieves optical breakdown (or photo disruption) with minimised energy levels.
Lumenis’ SLT is clinically proven as an effective primary therapy for glaucoma, with a recent study on Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension, presenting strong evidence for the use of SLT as a first-line therapy for the treatment of open-angle glaucoma (OAG)1.
With the Smart 532TM SmartPulseTM Sub-Threshold capabilities, the Smart Selecta® Trio™ features a uniform energy distribution across the entire laser spot for more precise and safer photocoagulation of the ocular tissue, eliminating the potential risk for the formation of ‘hot spots’. The Dual Fibre Port changes delivery from the device efficiently, offering the ability to automatically sense the delivery device connected to it, adjusting the laser parameters and compensating power density for target tissue.
Advanced component selection, laser delivery technology and enhanced slit lamp optics provide you with consistently optimal performance. Offering endless opportunities, the Trio can be further enhanced by adding LIO to your configuration.
Now available with SmartV, the Smart Selecta® Trio™ allows on-axis and off-axis illumination of SLT, YAG and Vitreous Opacities for stable, reliable and all-encompassing results.
Presenting unprecedented control, the Trio automatically runs internal tests to ensure that every laser pulse meets your exact power requirements and ensures patient safety and comfort.
Discover expert insight on other innovations revolutionising the vision and medicinal industry on The HUB. Discover virtual seminars, interactive training sessions and professional education. Find out more.
- Garg A, Vickerstaff V, Nathwani N, et al. Primary selective laser trabeculoplasty for open angle glaucoma and ocular hypertension: clinical outcomes, predicators of success and safety from the laser in glaucoma and ocular hypertension (LIGHT) trial. Ophthalmology. 2019;126(9):1238-1248.
PB-00016650 Rev A